8 completed, 1 terminated, 1 unknown, 1 withdrawn. 6 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 3 | Completed 3 |
Follow EVIVE Biotechnology: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia F-652, Placebo - COVID-19 Pneumonia | Phase 2 | Withdrawn | EVIVE Biotechnology | 2022-04-08 | 2023-10-02 | |
| Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19 F-652, Placebo - Covid19 | Phase 2 | Terminated | EVIVE Biotechnology | 1 | 2021-01-26 | 2023-12-21 |
| Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma Recombinant Anti-CD19m-CD3 Antibody Injection - Relapsed or Refractory B-cell Lymphoma | Phase 1 | Unknown | EVIVE Biotechnology | 54 | 2019-09-15 | 2019-08-14 |
| Study to Compare the Efficacy and Safety of F-627 and GRAN® F-627, GRAN® - Breast Cancer, Neutropenia | Phase 3 | Completed | EVIVE Biotechnology | 242 | 2018-04-12 | 2025-04-20 |
| Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy F-627, Neulasta - Breast Cancer, Neutropenia | Phase 3 | Completed | EVIVE Biotechnology | 393 | 2018-04-12 | 2023-07-03 |
| Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy F-627, Placebo - Breast Cancer, Neutropenia | Phase 3 | Completed | EVIVE Biotechnology | 122 | 2016-08-01 | 2021-05-05 |
| Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD Recombinant Human Interleukin-22 IgG2-Fc (F-652), Systemic Corticosteroids - Acute Graft vs Host Disease | Phase 1 / Phase 2 | Completed | EVIVE Biotechnology | 30 | 2016-05-12 | 2021-07-22 |
| A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy. F-627, Filgrastim - Neutropenia | Phase 2 | Completed | EVIVE Biotechnology | 138 | 2014-07-03 | 2018-02-23 |
| A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy F-627 240 μg/kg, F-627 320 μg/kg - Neutropenia | Phase 1 / Phase 2 | Completed | EVIVE Biotechnology | 15 | 2014-02-25 | 2019-11-21 |
| Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy F-627, EC regimen - Neutropenia, Breast Cancer | Phase 1 | Completed | EVIVE Biotechnology | 18 | 2012-12-01 | 2024-02-23 |
| Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy F-627, Neulasta® (pegfilgrastim) - Breast Cancer, Neutropenia | Phase 2 | Completed | EVIVE Biotechnology | 232 | 2012-06-01 | 2018-10-03 |
Neutropenia (7) · Breast Neoplasms (5) · COVID-19 (1) · Lymphoma, B-Cell (1) · Recurrence (1)
eflepedocokin alfa (3) · Filgrastim (2) · pegfilgrastim (2) · EC regimen (1) · Interleukin-22 (1)
United States (5) · China (3)
Junning Cao, Professor (2) · Christine M Bojanowski, MD (1) · Doris Ponce, M.D. (1) · Jin Li, Professor (1) · John Glaspy, MD (1) · Kevin F Dreyer (1) · Song Yuqin, Doctor (1) · Zhimin Shao, Doctor (1)
PMID 36399701, PMID 38103088, PMID 38194162, PMID 39272058, PMID 41066031